UK markets closed

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
77.84-0.87 (-1.11%)
At close: 05:36PM CEST
Full screen
Previous close78.71
Open78.22
Bid0.00 x 0
Ask0.00 x 0
Day's range77.26 - 78.53
52-week range76.45 - 106.66
Volume2,754,518
Avg. volume2,117,364
Market cap97.615B
Beta (5Y monthly)0.42
PE ratio (TTM)14.71
EPS (TTM)5.29
Earnings date28 Oct 2022
Forward dividend & yield3.33 (4.23%)
Ex-dividend date06 May 2022
1y target est106.58
  • Zacks

    Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis

    The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.

  • Zacks

    Is Novartis (NVS) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Globe Newswire

    Press Release: Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

    Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trialsAbout 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options Approval represents the second dermatology indication for Dupixent and fifth disease indication overall in the U.S. Paris and Tarrytown, N.Y. September 28, 2022